Stallergenes Greer
- Country
- 🇨🇦Canada
- Ownership
- -
- Established
- 2015-01-01
- Employees
- 1K
- Market Cap
- -
Clinical Trials
26
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (22 trials with phase data)• Click on a phase to view related trials
Evaluation of the Benefits of Sublingual AIT (PRACTIS)
- Conditions
- Allergic Rhinitis
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Stallergenes Greer
- Target Recruit Count
- 1635
- Registration Number
- NCT06574061
- Locations
- 🇫🇷
Stallergenes Greer, Antony, France
Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma
- Conditions
- Birch Pollen AllergyAllergic Rhinoconjunctivitis
- Interventions
- Drug: STALORAL® Birch 300 IR
- First Posted Date
- 2022-12-29
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Stallergenes Greer
- Target Recruit Count
- 699
- Registration Number
- NCT05668390
- Locations
- 🇦🇹
Allergie Zentrum Wien West, Vienna, Austria
🇦🇹VIENNA GENERAL HOSPITAL / Medical University of Vienna, Wien, Austria
🇦🇹Allergie Ambulatorium, Wien, Austria
Treatment Modalities in Children and Adolescents Suffering From HDM-induced Allergic Rhinitis and/or Asthma
- Conditions
- Allergy
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Stallergenes Greer
- Target Recruit Count
- 1531
- Registration Number
- NCT04004351
Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR
- Conditions
- Rhinitis, Allergic, PerennialHouse Dust Mite Allergy
- First Posted Date
- 2015-05-14
- Last Posted Date
- 2019-10-14
- Lead Sponsor
- Stallergenes Greer
- Target Recruit Count
- 1607
- Registration Number
- NCT02443805
- Locations
- 🇺🇸
University of South of Florida, Tampa, Florida, United States
🇫🇷CHU Arnaud de Villeneuve, Montpellier, France
Observational Study of Oralair® in Children 5-9 Years With Grass-pollen-induced Allergic Rhinitis With/Without Conjunctivitis
- Conditions
- Allergy
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- Stallergenes Greer
- Target Recruit Count
- 307
- Registration Number
- NCT02295969
- Locations
- 🇩🇪
Klinikum Augsburg, Klinik für Kinder und Jugendliche, Augsburg, Bavaria, Germany
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
Stallergenes Greer Transitions Actair® Promotional Activities from Shionogi to CEOLIA in Japan
Stallergenes Greer has appointed CEOLIA Pharma as its new promotional partner for Actair® in Japan, ending a 15-year licensing agreement with Shionogi that began in 2010.
Palforzia Receives European Commission Approval for Peanut Allergy Treatment in Toddlers
The European Commission has approved Palforzia for treating peanut allergies in toddlers aged 1-3, expanding its availability in Europe.
Palforzia Receives Positive CHMP Opinion for Peanut Allergy Treatment in Toddlers
The European Medicines Agency's CHMP has recommended Palforzia for treating peanut allergies in toddlers aged 1-3, marking a potential expansion of its use.
Nestlé Divests Palforzia to Stallergenes Greer, Exits Peanut Allergy Treatment Market
• Nestlé Health Science has sold its peanut allergy treatment Palforzia to Stallergenes Greer, just three years after acquiring Aimmune Therapeutics for $2.6 billion. • Despite being the first FDA-approved therapy for peanut allergy in children aged 4-17, Palforzia's market performance remained modest due to complex administration requirements and clinical monitoring challenges. • The acquisition positions Stallergenes Greer as the first company to offer both respiratory and food allergy treatments, while Nestlé retains future milestone payments and royalty rights.